<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00231790</url>
  </required_header>
  <id_info>
    <org_study_id>0634-007</org_study_id>
    <secondary_id>2005_045</secondary_id>
    <nct_id>NCT00231790</nct_id>
  </id_info>
  <brief_title>A Placebo-Controlled Study of MK0634 in Patients With Overactive Bladder (0634-007)</brief_title>
  <official_title>A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of MK0634 in Postmenopausal Women With Overactive Bladder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Overactive bladder is very prevalent in postmenopausal women. The current study is designed
      to investigate whether a new drug may offer safe and effective treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clinical development of MK-0634 was discontinued. Study MK-0634-027 was a safety follow-up
      study to determine if there were any ocular effects of MK-0634 in participants from the
      United Kingdom who were exposed to MK-0634 during the 007 study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">October 2006</completion_date>
  <primary_completion_date type="Actual">September 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in the number of micturitions per day averaged over a diary card week (4 to 10 days)</measure>
    <time_frame>Baseline and Week 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of participants with abnormal retinal photography (Follow-up Study 007 only)</measure>
    <time_frame>Day 1 of Follow-up</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of participants with abnormal visual field test (Follow-up Study 007 only)</measure>
    <time_frame>Day 1 of Follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the number of total incontinence episodes</measure>
    <time_frame>Baseline and Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of urge-incontinence episodes</measure>
    <time_frame>Up to 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of urgency episodes per day averaged over a diary card week (4 to 10 days)</measure>
    <time_frame>up to 8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">848</enrollment>
  <condition>Urinary Incontinence</condition>
  <arm_group>
    <arm_group_label>MK-0634 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will receive placebo for the 1 week prior to randomization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-0634 125 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will receive placebo for the 1 week prior to randomization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-0634 375 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will receive placebo for the 1 week prior to randomization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>All participants will receive placebo for the 1 week prior to randomization</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-0634 50 mg</intervention_name>
    <description>one capsule orally, once daily in morning</description>
    <arm_group_label>MK-0634 50 mg</arm_group_label>
    <other_name>L-000796568</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-0634 125 mg</intervention_name>
    <description>one or three capsules orally, once daily in morning</description>
    <arm_group_label>MK-0634 125 mg</arm_group_label>
    <arm_group_label>MK-0634 375 mg</arm_group_label>
    <other_name>L-000796568</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for MK-0634</intervention_name>
    <description>one, two, three or four capsules orally once daily in morning</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal females (ages 40-74) with predominantly urge urinary incontinence
             overactive bladder episodes.

          -  Patients must meet minimum eligibility requirements (e.g., average number of
             micturitions/day) based on screening diary cards.

        Exclusion Criteria:

          -  Patients must not suffer from diabetes insipidus

          -  Hyperglycemia

          -  Hypercalcemia

          -  Orthostatic hypotension

          -  Active/recurrent urinary tract infections (&gt;6 episodes per year)

          -  Patients must be willing to discontinue their current OAB medication therapy.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Ireland</country>
    <country>New Zealand</country>
    <country>South Africa</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2005</study_first_submitted>
  <study_first_submitted_qc>September 30, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2005</study_first_posted>
  <last_update_submitted>December 16, 2015</last_update_submitted>
  <last_update_submitted_qc>December 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

